Navitoclax, the first orally bioavailable Bcl-2 family inhibitor, inhibits Bcl-2 and Bcl-xL. Inhibition of the latter results in dose-limiting thrombocytopenia (18). This evidence concerns the gene BCL2 and Thrombocytopenia.